Refine
Has Fulltext
- yes (1)
Is part of the Bibliography
- yes (1)
Year of publication
- 2020 (1) (remove)
Document Type
- Journal article (1)
Language
- English (1)
Keywords
- Chimeric Antigen Receptor T cells (1)
- cancer (1)
- combined therapy (1)
- immunotherapy (1)
- metabolic reprogramming (1)
Institute
The adoptive transfer of the chimeric antigen receptor (CAR) expressing T-cells has produced unprecedented successful results in the treatment of B-cell malignancies. However, the use of this technology in other malignancies remains less effective. In the setting of solid neoplasms, CAR T-cell metabolic fitness needs to be optimal to reach the tumor and execute their cytolytic function in an environment often hostile. It is now well established that both tumor and T cell metabolisms play critical roles in controlling the immune response by conditioning the tumor microenvironment and the fate and activity of the T cells. In this review, after a brief description of the tumoral and T cell metabolic reprogramming, we summarize the latest advances and new strategies that have been developed to improve the metabolic fitness and efficacy of CAR T-cell products.